
Opinion|Videos|November 15, 2024
Addressing Payer Coverage Challenges
Key Takeaways
- Quadruplet regimens face payer coverage challenges, including prior authorization and high patient costs, impacting access to treatment.
- Providers address these challenges through proactive payer communication and presenting clinical evidence to support regimen efficacy.
Panelists discuss how they navigate challenges with payer coverage for quadruplet regimens in multiple myeloma treatment, including strategies they employ to address insurance denials or restrictions, such as providing clinical justification, leveraging recent trial data, and collaborating with financial assistance programs to ensure patients can access optimal therapy despite potential coverage difficulties.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- As a provider, have you noticed any difficulties regarding payer coverage for quadruplet regimens? If so, how have you addressed these challenges?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Enfortumab Vedotin Plus Pembrolizumab Shows Promise as a Platinum-Free Option in Earlier Bladder Cancer
2
FDA Approves Amivantamab and Hyaluronidase-lpuj, Revolutionizing Lung Cancer Treatment With 5-Minute Subcutaneous Delivery
3
Understanding Myelofibrosis and the Central Role of JAK Pathway Dysregulation
4
How Pharmacists Can Close the Opioid Addiction Care Gap
5








































































































































































































